Request Demo
Last update 13 Nov 2025
SSGJ-706
Last update 13 Nov 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms SSGJ 706, SSGJ-706, SSGJ706 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with SSGJ-706NCT07171606
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
NCT06533605
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Initial Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
CTR20253459
评估SSGJ-706单药或者联合治疗晚期非小细胞肺癌的开放、多中心II期临床研究
[Translation] An open-label, multicenter Phase II clinical study evaluating SSGJ-706 as a monotherapy or in combination therapy for the treatment of advanced non-small cell lung cancer
100 Clinical Results associated with SSGJ-706
Login to view more data
100 Translational Medicine associated with SSGJ-706
Login to view more data
100 Patents (Medical) associated with SSGJ-706
Login to view more data
100 Deals associated with SSGJ-706
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of large intestine | Phase 2 | China | 19 Sep 2025 | |
| Adenoma | Phase 2 | China | 19 Sep 2025 | |
| Adenosquamous Carcinoma | Phase 2 | China | 19 Sep 2025 | |
| Esophageal Squamous Cell Carcinoma | Phase 2 | China | 19 Sep 2025 | |
| Gastroesophageal junction adenocarcinoma | Phase 2 | China | 19 Sep 2025 | |
| Pancreatic Ductal Adenocarcinoma | Phase 2 | China | 19 Sep 2025 | |
| stomach adenocarcinoma | Phase 2 | China | 19 Sep 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 29 Aug 2025 | |
| Neoplasms | Phase 2 | United States | 14 Oct 2021 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free